Company news
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) news
Supernus Pharmaceuticals, Inc. news releases on 6ix. Latest, Aug 19, 2024: Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA
Press releases — page 2
Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA
August 18, 2024
Supernus Announces Second Quarter 2024 Financial Results
August 5, 2024
Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device
July 31, 2024
Supernus Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 6, 2024
July 22, 2024
Supernus Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
May 29, 2024
Supernus Announces Promising Interim Data from Ongoing Open-Label Phase 2a Study of SPN-817 in Epilepsy
May 22, 2024
Supernus Pharmaceuticals to Host Webcast to Review Interim Data from Ongoing Open-Label Phase IIa Study of SPN-817 for Treatment-Resistant Seizures
May 8, 2024
Supernus Announces First Quarter 2024 Financial Results
May 7, 2024
Busy Philipps Shines Spotlight on ADHD in Women and Shares her Qelbree Story
April 30, 2024
Supernus Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
April 23, 2024
Supernus Provides Regulatory Update for SPN-830
April 7, 2024
Supernus to Participate in the TD Cowen 44th Annual Healthcare Conference
February 27, 2024
Supernus Announces Fourth Quarter and Full Year 2023 Financial Results
February 26, 2024
Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on February 27, 2024
February 12, 2024
Supernus Wins Infringement and Validity Case on Trokendi XR® against Torrent
February 4, 2024
Supernus Announces Third Quarter 2023 Financial Results
November 7, 2023
Supernus to Participate in the Jefferies London Healthcare Conference
November 6, 2023
Supernus Pharmaceuticals to Announce Third Quarter 2023 Financial Results and Host Conference Call on November 8, 2023
October 24, 2023
Jay Glazer Teams Up with Supernus Pharmaceuticals to Raise Awareness of ADHD and his Qelbree® Journey
October 15, 2023
Supernus Pharmaceuticals Announces Webcast of R&D Day to be Held on October 18, 2023 in New York City
September 26, 2023
Supernus Announces New Qelbree® Data Showing Improvement in ADHD Symptoms
September 8, 2023
Supernus to Participate in the Wells Fargo Healthcare Conference
August 30, 2023
Bethany L. Sensenig Joins Supernus’ Board of Directors
August 20, 2023
Supernus Announces Second Quarter 2023 Financial Results
August 7, 2023
Supernus Pharmaceuticals to Announce Second Quarter 2023 Financial Results and Host Conference Call on August 8, 2023
July 23, 2023
Supernus to Participate in the Jefferies Healthcare Conference
May 30, 2023
Supernus Announces First Quarter 2023 Financial Results
May 8, 2023
Supernus to Present at the Bank of America 2023 Health Care Conference
May 1, 2023
Supernus Pharmaceuticals to Announce First Quarter 2023 Financial Results and Host Conference Call on May 9, 2023
April 24, 2023
Supernus Announces Repayment of Convertible Notes
April 2, 2023
Supernus to Present at the Cowen 43rd Annual Health Care Conference
February 28, 2023
Supernus Announces Fourth Quarter and Full Year 2022 Financial Results
February 27, 2023
Supernus Enters Into $150 Million Credit Facility
February 13, 2023
Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on February 28, 2023
February 8, 2023
Supernus to Present at the Piper Sandler 34th Annual Healthcare Conference
November 21, 2022
Supernus to Present at Two November Healthcare Conferences
November 7, 2022
Supernus Announces Third Quarter 2022 Financial Results
November 7, 2022
Supernus Pharmaceuticals to Announce Third Quarter 2022 Financial Results and Host Conference Call on November 8, 2022
October 24, 2022
Supernus Provides Regulatory Update on SPN-830
October 9, 2022
Supernus to Present at the 2022 Wells Fargo Healthcare Conference
August 30, 2022
Supernus Announces Second Quarter 2022 Financial Results
August 3, 2022
Supernus Pharmaceuticals to Announce Second Quarter 2022 Financial Results and Host Conference Call on August 4, 2022
July 24, 2022
Supernus Announces First Quarter 2022 Financial Results
May 8, 2022
Supernus Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host Conference Call on May 9, 2022
May 1, 2022
Supernus Announces FDA Approval of Qelbree® for the Treatment of ADHD in Adults
May 1, 2022
Supernus Reports Final Audited Fourth Quarter and Full Year 2021 Financial Results
April 12, 2022
Supernus Provides Update on Filing of Annual Report and Reiterates Full Year 2022 Financial Guidance
April 3, 2022
Supernus Notifies Nasdaq Regarding Non-Compliance with Listing Requirement and Expectation to Regain Compliance
March 16, 2022
Supernus to Participate in Annual Cowen Health Care Conference
March 1, 2022
Supernus Announces Preliminary Fourth Quarter and Full Year 2021 Financial Results
February 27, 2022